{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:56:48Z","timestamp":1789131408551,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.12.015","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T07:40:41Z","timestamp":1766734841000},"page":"169-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit"],"prefix":"10.1016","volume":"26","author":[{"given":"Cesar","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvan de Queiroz","family":"Crusoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Vieira","family":"Pericole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.12.015_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100808","article-title":"Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options","volume":"49","author":"Ramasamy","year":"2021","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.clml.2025.12.015_bib0003","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.12.015_bib0004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.12.015_bib0005","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.clml.2025.12.015_bib0006","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.12.015_bib0007","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.htct.2022.08.002","article-title":"CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil","volume":"45","author":"Hungria","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.clml.2025.12.015_bib0008","unstructured":"TECVAYLI\u24c7 solution for injection. Summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0009","unstructured":"TALVEY\u24c7 solution for injection. Summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf. Access date: January 15, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0010","unstructured":"ELREXFIO\u2122 solution for injection. Summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0011","unstructured":"CARVYKTI\u24c7 3.2\u202f\u00d7\u202f106 \u20131\u202f\u00d7\u202f108 cells dispersion for infusion. Summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0012","unstructured":"TALVEY\u24c7 (talquetamabe) solu\u00e7\u00e3o injet\u00e1vel. Identifica\u00e7\u00e3o do produto. 2024. https:\/\/assets.jnjlabels.com\/innovativemedicine\/latam\/brasil\/talvey-vp.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0013","unstructured":"TECVAYLI\u24c7 (teclistamabe) solu\u00e7\u00e3o injet\u00e1vel. Identifica\u00e7\u00e3o do produto. 2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20231207160927\/anx_160927_pt.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0014","unstructured":"ELREXFIO\u24c7 (elranatamabe) solu\u00e7\u00e3o injet\u00e1vel. Identifica\u00e7\u00e3o do medicamento. 2024. https:\/\/www.pfizer.com.br\/files\/Elrexfio_Profissional_de_Saude_10.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0015","unstructured":"TECVAYLI\u24c7 (teclistamab-cqyv) injection, for subcutaneous use. Prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761291s013lbl.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0016","unstructured":"TALVEY\u24c7 (talquetamab-tgvs) injection, for subcutaneous use. Prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0017","unstructured":"ELREXFIO\u2122 (elranatamab-bcmm) injection, for subcutaneous use. Prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345s000lbl.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0018","unstructured":"CARVYKTI\u24c7 (ciltacabtagene autoleucel) suspension for intravenous infusion. Prescribing information. 2024. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0019","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/j.htct.2023.09.753","article-title":"Teclistamab in relapsed or refractory multiple myeloma (RRMM): MajesTEC-1 subgroup analysis by lines of therapies","volume":"45","author":"van de Donk","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0020","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.clml.2025.12.015_bib0021","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen\u202f\u00d7\u202fCD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0022","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1182\/blood-2023-177968","article-title":"Patterns of response to 200 mg linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up of the Linker-MM1 study","volume":"142","author":"Jagannath","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0023","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0024","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0025","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2023-190793","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Asoori","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.12.015_bib0026","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.12.015_bib0027","first-page":"S99","article-title":"Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"24","author":"Ye","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0028","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S2152-2650(24)02346-2","article-title":"Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SOC) in lenalidomide (len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update","volume":"24","author":"Mateos","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"10.1016\/j.clml.2025.12.015_bib0029","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.015_bib0030","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0031","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2023-182330","article-title":"Clinical outcomes of subsequent therapies in patients with relapsed\/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Sanchez","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0032","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1182\/blood-2024-211739","article-title":"Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell redirecting therapies","volume":"144","author":"Castaneda","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.015_bib0033","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2024-210451","article-title":"Efficacy of anti-BCMA CAR-T cell therapies in multiple myeloma patients with prior exposure to bispecific antibodies- results from a retrospective multi-center registry analysis","volume":"144","author":"Waldschmidt","year":"2024","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.12.015_bib0034","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2025.12.015_bib0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.12.015_bib0036","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S2152-2650(24)01989-X","article-title":"Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed\/refractory multiple myeloma","volume":"24","author":"Tan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0037","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S2152-2650(24)01974-8","article-title":"Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the U.S. Myeloma Immunotherapy Consortium","volume":"24","author":"Razzo","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0038","first-page":"P929","article-title":"Effectiveness and safety of bispecific antibodies targeting BCMA and CD3 in patients with central nervous system multiple myeloma (CNS-MSS): IFM 2023-06, a retrospective cohort study","volume":"8","author":"Lachenal","year":"2024","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.clml.2025.12.015_bib0039","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1002\/ajh.27063","article-title":"Teclistamab in patients with multiple myeloma and impaired renal function","volume":"98","author":"Joiner","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.12.015_bib0040","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2023-180660","article-title":"Teclistamab in relapsed refractory multiple myeloma patients on dialysis: a French experience","volume":"142","author":"Lachenal","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.12.015_bib0041","doi-asserted-by":"crossref","first-page":"46","DOI":"10.46989\/001c.116800","article-title":"Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis","volume":"6","author":"Van de Wyngaert","year":"2024","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.clml.2025.12.015_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1276295","article-title":"Relapsed refractory multiple myeloma with CNS involvement successfully treated with elranatamab: first reported case","volume":"14","author":"Mutlu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2025.12.015_bib0043","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S2152-2650(24)01930-X","article-title":"Real world experience of standard of care talquetamab in patients with relapsed and refractory multiple myeloma","volume":"24","author":"Grajales-cruz","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0044","first-page":"S46","article-title":"Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed\/refractory multiple myeloma","volume":"24","author":"Costa","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0045","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S2152-2650(24)01982-7","article-title":"Real-world safety and efficacy of talquetamab for patients with heavily pretreated relapsed-refractory multiple myeloma","volume":"24","author":"Shaikh","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0046","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S2152-2650(24)01938-4","article-title":"Can bispecific T cell engagers for multiple myeloma be safely administered in the community? A single center experience","volume":"24","author":"Jiwani","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0047","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2024-204232","article-title":"Single center real world experience of talquetamab in patients with relapsed and refractory multiple myeloma","volume":"144","author":"Grajales-Cruz","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.12.015_bib0048","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.015_bib0049","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.clml.2025.12.015_bib0050","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2025.12.015_bib0051","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clml.2025.12.015_bib0052","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab","volume":"24","author":"Chari","year":"2024","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.12.015_bib0053","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2025.12.015_bib0054","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, Schinke CD, Chari A, et al. Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1. J Clin Oncol. 2023;41(Supplement 16):8020.","DOI":"10.1200\/JCO.2023.41.16_suppl.8020"},{"issue":"11","key":"10.1016\/j.clml.2025.12.015_bib0055","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/qjmed\/93.11.751","article-title":"Nephrotoxicity of intravenous immunoglobulin","volume":"93","author":"Levy","year":"2000","journal-title":"QJM"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0056","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2023-174270","article-title":"Real-world treatment outcomes of teclistamab under an outpatient model for step-up dosing administration","volume":"142","author":"Sandahl","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.12.015_bib0057","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/03007995.2024.2387183","article-title":"Real-world experience with clinical management of talquetamab in relapsed\/refractory multiple myeloma: a qualitative study of US healthcare providers","volume":"40","author":"Schinke","year":"2024","journal-title":"Curr Med Res Opin"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0058","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1182\/blood-2024-207295","article-title":"Optec: a phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM): updated results","volume":"144","author":"Rifkin","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0059","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood-2023-178896","article-title":"Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals - an updated analysis using premier healthcare database","volume":"142","author":"Tan","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0060","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1182\/blood-2024-203379","article-title":"Dosing patterns and early safety and effectiveness outcomes in patients with multiple myeloma treated with teclistamab in the community setting","volume":"144","author":"Beer","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0061","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1182\/blood-2024-206357","article-title":"Predictors and characterization of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients with multiple myeloma receiving teclistamab","volume":"144","author":"Pasvolsky","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.015_bib0062","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S2152-2650(24)01961-X","article-title":"Cytokine release syndrome in patients receiving alternative step-up doses of talquetamab for relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"24","author":"Morillo","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.clml.2025.12.015_bib0063","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0064","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1182\/blood-2024-200344","article-title":"Analysis of repeat step-up dosing and cytokine release syndrome events following prolonged dosing intervals of teclistamab in the phase 1\/2 MajesTEC-1 study","volume":"144","author":"van de Donk","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.015_bib0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"35","key":"10.1016\/j.clml.2025.12.015_bib0066","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.12.015_bib0067","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.12.015_bib0068","unstructured":"ACTEMRA\u24c7 (tocilizumab) injection, for intravenous use and subcutaneous use. Prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125276s114lbl.pdf. Access date: January 14, 2026."},{"key":"10.1016\/j.clml.2025.12.015_bib0069","unstructured":"National Comprehensive Cancer Network. Management of immunotherapy related toxicities version 1.2025. 2025; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Accessed: March 17, 2025."},{"key":"10.1016\/j.clml.2025.12.015_bib0070","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221100659","article-title":"Toxicity management strategies for next-generation novel therapeutics in multiple myeloma","volume":"13","author":"Steinbach","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2025.12.015_bib0071","doi-asserted-by":"crossref","first-page":"eAO6353","DOI":"10.31744\/einstein_journal\/2022AO6353","article-title":"Real world evidence of the use of metamizole (dipyrone) by the Brazilian population. A retrospective cohort with over 380,000 patients","volume":"20","author":"Sznejder","year":"2022","journal-title":"Einstein (Sao Paulo)"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0072","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood-2023-187086","article-title":"Tocilizumab prophylaxis for patients treated with teclistamab: a single-center experience","volume":"142","author":"Kowalski","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.015_bib0073","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.12.015_bib0074","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S2152-2650(24)01980-3","article-title":"Prophylactic tocilizumab to mitigate cytokine release syndrome in patients receiving talquetamab for relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"24","author":"Schinke","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0075","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Garfall AL, Benboubker L, et al. Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1. J Clin Oncol. 2023;41(Supplement 16):8033.","DOI":"10.1200\/JCO.2023.41.16_suppl.8033"},{"issue":"5","key":"10.1016\/j.clml.2025.12.015_bib0076","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050355","article-title":"Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas","volume":"11","author":"Salvaris","year":"2021","journal-title":"J Pers Med"},{"issue":"9","key":"10.1016\/j.clml.2025.12.015_bib0077","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/CAD.0000000000000814","article-title":"Tumour flare reaction in cancer treatments: a comprehensive literature review","volume":"30","author":"Taleb","year":"2019","journal-title":"Anticancer Drugs"},{"issue":"8","key":"10.1016\/j.clml.2025.12.015_bib0078","first-page":"1546","article-title":"How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy","volume":"9","author":"Ma","year":"2019","journal-title":"Am J Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2025.12.015_bib0079","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.015_bib0080","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.12.015_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2024.151712","article-title":"Nursing considerations for the clinical management of adverse events associated with talquetamab in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Catamero","year":"2024","journal-title":"Semin Oncol Nurs"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2025.12.015_bib0082","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1016\/S2152-2650(23)02113-4","article-title":"Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"23","author":"Purcell","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0083","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S2152-2650(24)01969-4","article-title":"Prophylactic interventions for oral toxicities with the GPRC5D\u00d7CD3 bispecific antibody talquetamab in relapsed\/refractory multiple myeloma: an open-label, phase 2, randomized study (TALISMAN)","volume":"24","author":"Popat","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.015_bib0084","unstructured":"Stansfield N. The CAR-T versus bispecific antibody debate in third line LBCL. 2024; https:\/\/www.cgtlive.com\/view\/car-t-versus-bispecific-antibody-debate-third-line-lbcl. Accessed: November 01, 2024."},{"issue":"10297","key":"10.1016\/j.clml.2025.12.015_bib0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2025.12.015_bib0086","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.12.015_bib0087","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41571-024-00927-6","article-title":"BCMA-directed therapy for early relapsed and\/or refractory multiple myeloma","volume":"21","author":"van de Donk","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.015_bib0088","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1097\/RLU.0000000000004588","article-title":"2-[18F]FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma","volume":"48","author":"Jamet","year":"2023","journal-title":"Clin Nuc Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502504323X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502504323X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:43:57Z","timestamp":1780991037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502504323X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S215226502504323X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}